Naphthoquinone Composition to Reduce Anticancer Treatment Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer-related side effects such as fatigue, cachexia, pain, cognitive decline, and hematopoietic stem cell reduction during anticancer drug treatment are inadequate, primarily focusing on symptom relief rather than addressing the underlying mechanisms, particularly the excessive production of inflammatory cytokines.
Innovation Solution
The use of naphthoquinone-based compounds, specifically dunnione and β-lapachone, to inhibit the secretion and production of inflammatory cytokines, thereby alleviating fatigue, cachexia, pain, and preserving hematopoietic stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anticancer drugs are used to treat cancer, then cancer cells are eliminated, but inflammatory cytokines are over-produced causing fatigue, cachexia, pain and cognitive decline
Solution Approach 1:
The patent introduces naphthoquinone-based compounds as intermediary substances that mediate between anticancer drugs and inflammatory cytokines. These compounds specifically target and inhibit the over-production of inflammatory cytokines (IL-1, IL-6, TNF-α) without interfering with the anticancer mechanism, thereby reducing side effects while maintaining treatment effectiveness
Solution Approach 2:
The patent extracts and addresses the harmful component (inflammatory cytokines) separately from the cancer cells. By using naphthoquinone-based compounds to specifically inhibit cytokine production, the treatment isolates and eliminates the harmful inflammatory response while preserving the therapeutic effect on cancer cells
2Reliability
If anticancer chemotherapy is administered, then cancer progression is blocked, but hematopoietic stem cells are depleted
Solution Approach 1:
The naphthoquinone-based compounds act as intermediary protectors for hematopoietic stem cells. They interfere with the inflammatory cytokine pathway that would otherwise accelerate stem cell differentiation and depletion, thereby preserving stem cell quantity and function during chemotherapy
Solution Approach 2:
The patent applies preliminary protective action by administering naphthoquinone-based compounds before or during chemotherapy to prevent the inflammatory cascade that leads to stem cell depletion. This preemptive approach counteracts the harmful effects before they fully manifest
3Reliability
If cytokine production is increased to fight cancer, then immune response is enhanced, but side effects such as fatigue and cognitive decline worsen
Solution Approach 1:
The patent applies local quality control by selectively targeting specific inflammatory cytokines (IL-1, IL-6, TNF-α) rather than suppressing the entire immune response. The naphthoquinone-based compounds specifically inhibit these harmful cytokines while allowing other beneficial immune responses to proceed normally
Solution Approach 2:
The patent converts the harmful over-production of inflammatory cytokines into a beneficial controlled response. By using naphthoquinone-based compounds to regulate cytokine levels, the treatment maintains the necessary immune activation against cancer while preventing the excessive inflammation that causes fatigue and cognitive decline
Data Source
AI summary
A composition comprising a naphthoquinone-based compound as an active ingredient and uses thereof are disclosed. The composition is effective for preventing or ameliorating fatigue, cachexia, pain, cognitive decline, and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment. The naphthoquinone-based compounds, dunnione and β-lapachone, reduce the secretion and production of inflammatory cytokines which are increased by the anticancer drug treatment, and prevent fatigue, cachexia, cognitive decline, and hematopoietic stem cell reduction which are side effects associated with anticancer drug treatment.